Nature Communications (Apr 2024)

Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells

  • Mike B. Barnkob,
  • Yale S. Michaels,
  • Violaine André,
  • Philip S. Macklin,
  • Uzi Gileadi,
  • Salvatore Valvo,
  • Margarida Rei,
  • Corinna Kulicke,
  • Ji-Li Chen,
  • Vitul Jain,
  • Victoria K. Woodcock,
  • Huw Colin-York,
  • Andreas V. Hadjinicolaou,
  • Youxin Kong,
  • Viveka Mayya,
  • Julie M. Mazet,
  • Gracie-Jennah Mead,
  • Joshua A. Bull,
  • Pramila Rijal,
  • Christopher W. Pugh,
  • Alain R. Townsend,
  • Audrey Gérard,
  • Lars R. Olsen,
  • Marco Fritzsche,
  • Tudor A. Fulga,
  • Michael L. Dustin,
  • E. Yvonne Jones,
  • Vincenzo Cerundolo

DOI
https://doi.org/10.1038/s41467-024-47424-z
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Semaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely understood. Here we demonstrate that Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 are upregulated on stimulated CD8+ T cells, allowing tumour-derived SEMA3A to inhibit T cell migration and assembly of the immunological synapse. Deletion of NRP1 in both CD4+ and CD8+ T cells enhance CD8+ T-cell infiltration into tumours and restricted tumour growth in animal models. Conversely, over-expression of SEMA3A inhibit CD8+ T-cell infiltration. We further show that SEMA3A affects CD8+ T cell F-actin, leading to inhibition of immune synapse formation and motility. Examining a clear cell renal cell carcinoma patient cohort, we find that SEMA3A expression is associated with reduced survival, and that T-cells appear trapped in SEMA3A rich regions. Our study establishes SEMA3A as an inhibitor of effector CD8+ T cell tumour infiltration, suggesting that blocking NRP1 could improve T cell function in tumours.